Xingjuan Chao Sells 3,372 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao sold 3,372 shares of the business’s stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $15.03, for a total value of $50,681.16. Following the sale, the chief executive officer now directly owns 743,079 shares of the company’s stock, valued at $11,168,477.37. This represents a 0.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Thursday, April 17th, Xingjuan Chao sold 5,700 shares of CeriBell stock. The shares were sold at an average price of $15.02, for a total value of $85,614.00.

CeriBell Stock Performance

Shares of NASDAQ CBLL opened at $14.77 on Wednesday. The company has a fifty day moving average of $20.02. CeriBell has a 52-week low of $10.01 and a 52-week high of $32.75.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. On average, equities analysts forecast that CeriBell will post -2.46 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on CBLL. LADENBURG THALM/SH SH initiated coverage on shares of CeriBell in a report on Friday, April 4th. They set a “buy” rating and a $32.00 price target on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $33.00 target price on shares of CeriBell in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $32.50.

Institutional Investors Weigh In On CeriBell

Large investors have recently bought and sold shares of the business. FMR LLC purchased a new position in shares of CeriBell in the 4th quarter worth $128,120,000. TPG GP A LLC purchased a new position in CeriBell in the fourth quarter worth about $102,677,000. Red Tree Management LLC bought a new stake in CeriBell during the fourth quarter worth approximately $57,083,000. Yu Fan bought a new stake in shares of CeriBell in the 4th quarter valued at approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd purchased a new position in shares of CeriBell in the 4th quarter worth approximately $28,160,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.